



NEWS RELEASE

Foundation Medicine to Collaborate with Eisai on International Oncology Clinical Trial

Prospective genomic profiling of patients will help stratify enrollment and provide insight for clinical trial outcomes

CAMBRIDGE, Mass. October 9, 2012 – [Foundation Medicine, Inc.](#) announced today a multi-year collaboration with Eisai Co., Ltd., Tokyo, Japan for genomic profiling and diagnostic discovery in a multi-site, international clinical trial of an Eisai targeted therapeutic candidate. The goal of the collaboration is to prospectively identify specific genomic alterations in each patient’s tumor and use the results to inform patient stratification, to guide drug development decisions and potentially for the commercialization of new molecular diagnostics. Foundation Medicine will receive an upfront payment and is eligible for future diagnostic rights.

“Eisai is dedicated to bringing new treatment options to cancer patients,” said Takashi Owa, Ph.D., chief innovation officer, Eisai. “This collaboration with Foundation Medicine, utilizing their depth of molecular oncology knowledge and ability to partner on a global scale, will help Eisai better understand the genomic makeup of each patient as we work to deliver new targeted treatments that may benefit patients.”

“This collaboration represents the continued advancement of our partnership strategy as we gain greater understanding into the key alterations driving tumor growth,” said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. “By using our comprehensive genomic profile to inform trial enrollment and outcomes analysis, Eisai can reveal the genomic drivers of an individual patient’s disease and may be able to more rapidly advance effective targeted treatments for cancer.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical product, [FoundationOne™](#), is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.foundationmedicine.com.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based *human health care (hhc)* company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai, please visit www.eisai.com.

Contact:

Foundation Medicine

Dan Budwick
Pure Communications, Inc.
(973) 271-6085

Sheryl Seapy
Pure Communications, Inc.
(949) 608-0841

###